FdaApplication
BLA 761081
Identifiers
- fda_app_no: BLA761081
Properties
| Property | Value |
|---|---|
| applicant_name | Pfizer Ireland Pharmaceuticals Unlimited Company |
| application_type | BLA |
| approval_date | 2019-03-11 |
Revenue by product
TRAZIMERA
| Period | Revenue |
|---|---|
| Q4 2023 | $24.0M |
| Q3 2023 | $0.0M |
| Q2 2023 | $33.0M |
| Q1 2023 | $34.0M |
| Q4 2022 | $54.0M |
| Q3 2022 | $51.0M |
| Q2 2022 | $46.0M |
| Q1 2022 | $52.0M |
| Q4 2021 | $66.0M |
| Q3 2021 | $45.0M |
| Q2 2021 | $41.0M |
| Q1 2021 | $45.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
TRAZIMERA
| Period | Revenue |
|---|---|
| Q4 2023 | $24.0M |
| Q3 2023 | $0.0M |
| Q2 2023 | $33.0M |
| Q1 2023 | $34.0M |
| Q4 2022 | $54.0M |
| Q3 2022 | $51.0M |
| Q2 2022 | $46.0M |
| Q1 2022 | $52.0M |
| Q4 2021 | $66.0M |
| Q3 2021 | $45.0M |
| Q2 2021 | $41.0M |
| Q1 2021 | $45.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TRAZIMERA | TRASTUZUMAB-QYYP | 420MG | For Injection |
| TRAZIMERA | — | 150MG | For Injection |
2 products